Integrating Pharmacogenomics at an Early Stage into Drug Development
This article was originally published in SRA
Linda Surh and David Laurie et al discuss regulatory moves to incorporate pharmacogenomic analysis in the drug development process.
You may also be interested in...
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.
The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.